Novel Bio

NovelBio is a Shanghai-based biotechnology company that integrates advanced bioinformatics, multi-omics data, and drug discovery to develop innovative therapies. The company operates the proprietary NovelBrain cloud platform, which provides high-throughput genomic analysis, single-cell sequencing, and spatial transcriptomics services to academic and pharmaceutical partners. In addition to its role as a leading bioinformatics CRO, NovelBio is advancing an internal pipeline of biologics, including multi-specific fusion proteins and monoclonal antibodies targeting oncology indications. Their lead program, NB001, is a PD-L1/IL-15 fusion protein designed to enhance anti-tumor immune responses by simultaneously blocking inhibitory signals and activating immune effectors.